These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 26311446)

  • 1. Baseline symptom severity predicts serotonin transporter change during psychotherapy in patients with major depression.
    Joensuu M; Ahola P; Knekt P; Lindfors O; Saarinen P; Tolmunen T; Valkonen-Korhonen M; Vanninen R; Jääskeläinen T; Virtala E; Kuikka J; Tiihonen J; Lehtonen J
    Psychiatry Clin Neurosci; 2016 Jan; 70(1):34-41. PubMed ID: 26311446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in midbrain serotonin transporter availability in atypically depressed subjects after one year of psychotherapy.
    Lehto SM; Tolmunen T; Joensuu M; Saarinen PI; Valkonen-Korhonen M; Vanninen R; Ahola P; Tiihonen J; Kuikka J; Lehtonen J
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):229-37. PubMed ID: 17884269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated midbrain serotonin transporter availability in mixed mania: a case report.
    Tolmunen T; Joensuu M; Saarinen PI; Mussalo H; Ahola P; Vanninen R; Kuikka J; Tiihonen J; Lehtonen J
    BMC Psychiatry; 2004 Sep; 4():27. PubMed ID: 15363105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced midbrain serotonin transporter availability in drug-naïve patients with depression measured by SERT-specific [(123)I] nor-beta-CIT SPECT imaging.
    Joensuu M; Tolmunen T; Saarinen PI; Tiihonen J; Kuikka J; Ahola P; Vanninen R; Lehtonen J
    Psychiatry Res; 2007 Feb; 154(2):125-31. PubMed ID: 17289353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors.
    Kugaya A; Sanacora G; Staley JK; Malison RT; Bozkurt A; Khan S; Anand A; Van Dyck CH; Baldwin RM; Seibyl JP; Charney D; Innis RB
    Biol Psychiatry; 2004 Oct; 56(7):497-502. PubMed ID: 15450785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study.
    Newberg AB; Amsterdam JD; Wintering N; Ploessl K; Swanson RL; Shults J; Alavi A
    J Nucl Med; 2005 Jun; 46(6):973-7. PubMed ID: 15937308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantifying midbrain serotonin transporter in depression: a preliminary study of diagnosis and naturalistic treatment outcome.
    Tsai HC; Lin SH; Chen PS; Chang HH; Lee IH; Yeh TL; Chen KC; Chiu NT; Yao WJ; Liao MH; Yang YK
    Pharmacopsychiatry; 2015 Mar; 48(2):58-64. PubMed ID: 25626060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disproportionate Reduction of Serotonin Transporter May Predict the Response and Adherence to Antidepressants in Patients with Major Depressive Disorder: A Positron Emission Tomography Study with 4-[18F]-ADAM.
    Yeh YW; Ho PS; Kuo SC; Chen CY; Liang CS; Yen CH; Huang CC; Ma KH; Shiue CY; Huang WS; Shyu JF; Wan FJ; Lu RB; Huang SY
    Int J Neuropsychopharmacol; 2015 Jan; 18(7):pyu120. PubMed ID: 25568284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midbrain serotonin and striatum dopamine transporter binding in double depression: a one-year follow-up study.
    Lehto SM; Tolmunen T; Kuikka J; Valkonen-Korhonen M; Joensuu M; Saarinen PI; Vanninen R; Ahola P; Tiihonen J; Lehtonen J
    Neurosci Lett; 2008 Aug; 441(3):291-5. PubMed ID: 18588943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower availability of midbrain serotonin transporter between healthy subjects with and without a family history of major depressive disorder - a preliminary two-ligand SPECT study.
    Hsieh PC; Chen KC; Yeh TL; Lee IH; Chen PS; Yao WJ; Chiu NT; Chen CC; Liao MH; Yang YK
    Eur Psychiatry; 2014 Sep; 29(7):414-8. PubMed ID: 24439516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding potential changes of SERT in patients with depression are associated with remission: A prospective [¹²³I]β-CIT-SPECT study.
    Krause D; Chrobok A; Karch S; Keeser D; Manz KM; Koch W; Brendel M; Rominger A; Koller G; Behle N; Pogarell O
    Exp Clin Psychopharmacol; 2023 Feb; 31(1):219-227. PubMed ID: 35604719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder.
    Ruhé HG; Ooteman W; Booij J; Michel MC; Moeton M; Baas F; Schene AH
    Pharmacogenet Genomics; 2009 Jan; 19(1):67-76. PubMed ID: 18987562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probing the Serotonin Transporter Availability Among Male Cigarette Smokers: A SPECT Study With [123I] ADAM.
    Zhao RJ; Lin SH; Lee LT; Lee IH; Chen PS; Chen KC; Yang YK
    J Addict Med; 2016; 10(2):89-92. PubMed ID: 26742023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midbrain binding of [123I]nor-beta-CIT in atypical depression.
    Lehto S; Tolmunen T; Joensuu M; Saarinen PI; Vanninen R; Ahola P; Tiihonen J; Kuikka J; Lehtonen J
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1251-5. PubMed ID: 16644083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An outcome of psychodynamic psychotherapy: a case study of the change in serotonin transporter binding and the activation of the dream screen.
    Saarinen PI; Lehtonen J; Joensuu M; Tolmunen T; Ahola P; Vanninen R; Kuikka J; Tiihonen J
    Am J Psychother; 2005; 59(1):61-73. PubMed ID: 15895769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diencephalic serotonin transporter availability predicts both transporter occupancy and treatment response to sertraline in obsessive-compulsive checkers.
    Zitterl W; Stompe T; Aigner M; Zitterl-Eglseer K; Ritter K; Zettinig G; Hornik K; Asenbaum S; Pirker W; Thau K
    Biol Psychiatry; 2009 Dec; 66(12):1115-22. PubMed ID: 19717141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association study of serotonin transporter availability and SLC6A4 gene polymorphisms in patients with major depression.
    Ho PS; Ho KK; Huang WS; Yen CH; Shih MC; Shen LH; Ma KH; Huang SY
    Psychiatry Res; 2013 Jun; 212(3):216-22. PubMed ID: 23149035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender.
    Ruhé HG; Booij J; Reitsma JB; Schene AH
    Eur J Nucl Med Mol Imaging; 2009 May; 36(5):841-9. PubMed ID: 19183998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study.
    Catafau AM; Perez V; Plaza P; Pascual JC; Bullich S; Suarez M; Penengo MM; Corripio I; Puigdemont D; Danus M; Perich J; Alvarez E
    Psychopharmacology (Berl); 2006 Dec; 189(2):145-53. PubMed ID: 17033844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probing the association between dexamethasone-induced cortisol suppression and serotonin transporter availability among drug-free patients with major depressive disorder--a small-sample SPECT study with [¹²³I]ADAM.
    Tsai HC; Lin SH; Lee IH; Chen PS; Chen KC; Yeh TL; Yao WJ; Chiu NT; Lu RB; Yang YK
    Psychoneuroendocrinology; 2013 Nov; 38(11):2805-9. PubMed ID: 23816429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.